Peptide News Digest

#375-Patients

2 stories

Industry · View digest

Roivant Analyst Price Targets Continue Rising Through Mid-Week Following Pulmovant PHocus Phase 2 Win: TD Cowen to $55 (From $50), Jefferies to $52 (From $42)

Sell-side analyst upgrades on Roivant Sciences (NASDAQ: ROIV) continued through Wednesday-Thursday September 9-10, 2026 following the Tuesday September 8 Pulmovant Phase 2 PHocus win in pulmonary hypertension associated with interstitial lung disease. TD Cowen raised its ROIV price target to $55 from $50 with a Buy rating; Jefferies raised to $52 from $42 with a Buy rating. These upgrades follow the Guggenheim ($46 from $42) and Piper Sandler ($55 from $40) targets published Wednesday September 9. Guggenheim estimated peak sales of approximately $3 billion in PH-ILD. Consensus analyst estimates now cluster around a $50-55 target range. The PHocus study achieved a 56.3% placebo-adjusted reduction in pulmonary vascular resistance at Week 16 (p<0.0001) with placebo-adjusted improvements of +35.2 meters six-minute walk distance and −53.2% NT-proBNP from baseline. The Phase 3 PHrontier study is enrolling approximately 375 patients globally in a 1:1 randomized double-blind placebo-controlled design.

Clinical Trials · View digest

Pulmovant Mosliciguat Phase 2 PHocus Trial Meets Primary Endpoint With Placebo-Adjusted 56.3% PVR Reduction at Week 16 in PH-ILD; Phase 3 PHrontier Enrolling

Pulmovant, a Roivant Sciences (NASDAQ: ROIV) company, announced Tuesday September 8, 2026 that the Phase 2 PHocus study of inhaled mosliciguat (a once-daily first-in-class inhaled soluble guanylate cyclase activator) met its primary endpoint in patients with pulmonary hypertension associated with interstitial lung disease. Placebo-adjusted pulmonary vascular resistance reduction was 56.3% at Week 16 (-51.3% mosliciguat vs +6.6% placebo, p<0.0001) — the largest PVR reduction reported in any randomized controlled pulmonary hypertension trial per Pulmovant. Secondary endpoints: placebo-adjusted six-minute walk distance +35.2 meters (p=0.0027) and NT-proBNP -357.7 pg/mL, a 53.2% reduction from baseline (p=0.0002). At Week 24 (exploratory), 6MWD was +52.7 meters placebo-adjusted and NT-proBNP was -487.1 pg/mL (-75.9%). Mosliciguat was well-tolerated with lower cough incidence (12.1%) than placebo (18.2%). The trial enrolled 135 patients across 87 sites in 20 countries. The Phase 3 PHrontier study is enrolling approximately 375 patients globally in a 1:1 randomized double-blind placebo-controlled design. Marc Humbert (Université Paris-Saclay) presented the data at the ERS Congress in Barcelona; Roivant shares closed up approximately 17% on the day. Mosliciguat activates sGC independently of heme and nitric oxide, differentiating it from sGC stimulators like riociguat.